Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients

Bone Marrow Transplantation volume 26, pages 17–22 (2000)Cite this article

Abstract

One hundred and thirty-one patients were transplanted for AML-CR1, ALL-CR1 or CML-CP1 after conditioning with 120 mg/kg body weight cyclophosphamide and 2 × 4.5 Gy TBI. Conditioning was intensified with the addition of 42 mg/m2 idarubicin. Grafts were T cell-depleted using counterflow centrifugation. Donors were HLA-identical siblings. We compared outcome of BMT in 109 patients aged less than 50 (median, 35) years with that of 22 patients with an age of 50 years or more (median, 53 years). For the patients aged <50 years, 2-year probabilities of treatment-related mortality, relapse, survival and leukemia-free survival were 26% (95% CI, 17% to 35%), 26% (95% CI, 17% to 35%), 64% (95% CI, 55% to 73%), and 56% (95% CI, 47% to 65%). For the patients aged ⩾50 years, these figures were 13% (95% CI, 0% to 30%), 24% (95% CI, 6% to 42%), 66% (95% CI, 46% to 86%), and 67% (95% CI, 47% to 87%), respectively. outcome did not differ significantly between the two age groups. TRM was within the range of that reported in the literature for recipients of T cell-depleted grafts. We conclude that T cell-depleted transplantation after a conditioning regimen that was intensified with the addition of idarubicin is feasible in patients aged ⩾50 years. For this age group of patients, results of nonmyeloablative regimens should be compared with that obtained with T cell-depleted grafts. Bone Marrow Transplantation (2000) 26, 17–22.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute-graft-versus host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG) Bone Marrow Transplant 1997 19: 577–600

    Article  CAS  PubMed  Google Scholar 

  2. Gale RP, Bortin MM, Van Bekkum DW et al. Risk factors for acute graft-versus-host disease Br J Haematol 1987 67: 397–406

    Article  CAS  PubMed  Google Scholar 

  3. Maraninchi D, Blaise D, Rio B et al. Impact of T cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias Lancet 1987 2: 175–178

    Article  CAS  PubMed  Google Scholar 

  4. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myeloid leukemia in chronic phase: increased rate of relapse associated with T cell depletion Ann Intern Med 1988 108: 806–814

    Article  CAS  PubMed  Google Scholar 

  5. Marmont AM, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplants in leukemia Blood 1991 78: 2120–2130

    CAS  PubMed  Google Scholar 

  6. Muus P, DeWitte T, Schattenberg A et al. Intensification of the conditioning regimen for allogeneic bone marrow transplantation in recipients of T cell-depleted grafts by the addition of anthracyclines Leuk Lymphoma 1992 7: 11–14

    Article  Google Scholar 

  7. Giralt S, Estey E, Albitar M et al. Engraftment of hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  8. Khouri IF, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J CIin Oncol 1998 16: 2817–2824

    Article  CAS  Google Scholar 

  9. Schattenberg A, Preijers F, Mensink E et al. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia-chromosome positive CML in first chronic phase Bone Marrow Transplant 1997 19: 1205–1212

    Article  CAS  PubMed  Google Scholar 

  10. Schaap N, Schattenberg A, Bär B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen Br J Haematol 1997 98: 750–759

    Article  CAS  PubMed  Google Scholar 

  11. Glucksberg H, Storb R, Fefer A et al. CIinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  PubMed  Google Scholar 

  12. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man Am J Med 1980 69: 204–217

    Article  CAS  PubMed  Google Scholar 

  13. Kolb H-J, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 1995 86: 2041–2050

    CAS  PubMed  Google Scholar 

  14. Ringdén O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults JAMA 1993 270: 57–60

    Article  PubMed  Google Scholar 

  15. Soiffer RJ, Murray C, Mauch P et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow J CIin Oncol 1992 10: 1191–1200

    Article  CAS  Google Scholar 

  16. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time – a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT) Bone Marrow Transplant 1996 17: 1–18

    Google Scholar 

  17. Keating S, Suciu S, DeWitte T et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) leukemia cooperative groups Bone Marrow Transplant 1996 17: 993–1001

    CAS  PubMed  Google Scholar 

  18. Sullivan KM, Storb R, Buckner DC et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms New Engl J Med 1989 320: 828–834

    Article  CAS  PubMed  Google Scholar 

  19. Naparstek E, Or R, Nagler A et al. T cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse Br J Haematol 1995 89: 506–515

    Article  CAS  PubMed  Google Scholar 

  20. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Medical Center St Radboud, Nijmegen, The Netherlands

    A Schattenberg, N Schaap & T de Witte

  2. Central Hematology Laboratory, University Medical Center St Radboud, Nijmegen, The Netherlands

    F Preijers

  3. Department of Radiotherapy, University Medical Center St Radboud, Nijmegen, The Netherlands

    R van der Maazen

Authors
  1. A Schattenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Schaap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Preijers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R van der Maazen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schattenberg, A., Schaap, N., Preijers, F. et al. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant 26, 17–22 (2000). https://doi.org/10.1038/sj.bmt.1702451

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702451

Keywords

This article is cited by

Search

Advanced search

Quick links